Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes

NCT00365170 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00365170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00365170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2002
Completion date
April 30, 2005
Enrollment
419 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 1